Diabetic gastroparesis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Diabetic gastroparesis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Safety Study of Tradipitant for Patients with Idiopathic or Diabetic Gastroparesis https://clinicaltrials.eu/trial/safety-study-of-tradipitant-for-patients-with-idiopathic-or-diabetic-gastroparesis/ Wed, 29 Apr 2026 15:02:02 +0000 https://clinicaltrials.eu/trial/safety-study-of-tradipitant-for-patients-with-idiopathic-or-diabetic-gastroparesis/ This clinical trial is focused on studying a condition known as gastroparesis, which affects the stomach’s ability to empty food properly. The study specifically looks at two types of gastroparesis: idiopathic gastroparesis, where the cause is unknown, and diabetic gastroparesis, which occurs in people with diabetes. Patients involved in this study experience moderate to severe nausea as a symptom of their gastroparesis. The treatment being tested is a medication called tradipitant, also known by its code name VLY-686. This medication is taken in the form of a capsule.

The purpose of the study is to evaluate the safety of using tradipitant in patients with gastroparesis. Participants will take the medication over a period of three months. During this time, researchers will monitor the patients for any side effects or changes in their health. This includes checking for any adverse events, such as changes in mood or behavior, as well as monitoring vital signs, laboratory test results, heart function through electrocardiograms (ECGs), and physical health assessments.

The study is designed to ensure that the medication is safe for patients to use. Participants will be asked to keep a daily diary of their symptoms and follow certain guidelines, such as avoiding other medications that could interfere with the study. The trial aims to provide valuable information on how tradipitant can be used to help manage symptoms of gastroparesis safely.

]]> Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-naronapride-for-adults-with-moderate-idiopathic-or-diabetic-gastroparesis/ Wed, 29 Apr 2026 15:01:10 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-naronapride-for-adults-with-moderate-idiopathic-or-diabetic-gastroparesis/ This clinical trial is focused on studying a condition known as gastroparesis, which is a disorder that affects the normal movement of the stomach muscles, leading to delayed stomach emptying. The study specifically looks at two types of this condition: idiopathic gastroparesis, where the cause is unknown, and diabetic gastroparesis, which occurs in people with diabetes. The treatment being tested is a medication called Naronapride, which is taken as a film-coated tablet. The purpose of the study is to evaluate the effectiveness, safety, and tolerability of Naronapride in treating symptoms of gastroparesis over a 12-week period.

Participants in the study will be randomly assigned to receive either the Naronapride tablets or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The trial aims to find the optimal dose of Naronapride that provides the best balance of effectiveness and safety for patients with gastroparesis.

Throughout the study, participants will be monitored for changes in their symptoms, such as nausea, early satiety (feeling full quickly), postprandial fullness (feeling full after meals), upper abdominal pain, vomiting episodes, and bloating. The goal is to see if Naronapride can improve these symptoms compared to the placebo. The study will last for 12 weeks, during which participants will have regular check-ups to assess their progress and any side effects they may experience. This research is important for finding better ways to manage gastroparesis and improve the quality of life for those affected by this condition.

]]>